STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLDX
  4. [Form 4] Celldex Therapeutics, Inc. Insider Trading Activity

Celldex (CLDX) director awarded 26,000-share stock option grant as compensation

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Celldex Therapeutics director Neil Garry Arthur received a compensation-related stock option grant. He was awarded non-qualified options to acquire 26,000 shares of Celldex common stock at an exercise price of $34.09 per share under the company’s 2021 Omnibus Equity Incentive Plan. These options become exercisable starting on June 25, 2027 and expire on June 25, 2036, and this grant represents the full 26,000 derivative shares reported as held following the transaction.

Positive

  • None.

Negative

  • None.
Insider NEIL GARRY ARTHUR
Role null
Type Security Shares Price Value
Grant/Award Non-Qualified Stock Option (right to buy) 26,000 $0.00 --
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 26,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 26,000 shares Non-qualified stock options granted to director
Exercise price $34.09 per share Strike price for the 26,000 options
Total derivative holdings 26,000 shares Derivative shares following the transaction
Option exercisability date June 25, 2027 Date options first become exercisable
Option expiration date June 25, 2036 Final expiration of the option grant
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
2021 Omnibus Equity Incentive Plan financial
"option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
derivative transaction financial
"derivativeTransactionCount: 1"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
NEIL GARRY ARTHUR
(Last)(First)(Middle)
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 202
(Street)
HAMPTON NEW JERSEY 08827
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy)(1)$34.0906/25/2026(1)A26,00006/25/202706/25/2036Common Stock26,000$026,000D
Explanation of Responses:
1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
/s/ Sam Martin, attorney-in-fact for Garry A. Neil, M.D.06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Celldex Therapeutics (CLDX) director Neil Garry Arthur report in this Form 4?

Neil Garry Arthur reported receiving a non-qualified stock option grant for 26,000 shares of Celldex common stock. The options were granted as compensation under the 2021 Omnibus Equity Incentive Plan at a fixed exercise price.

How many Celldex (CLDX) shares are covered by Neil Garry Arthur’s new options?

The grant covers options to purchase 26,000 shares of Celldex common stock. This entire 26,000-share option position is shown as the total derivative holdings following the reported transaction in the Form 4 filing.

What is the exercise price of Neil Garry Arthur’s Celldex (CLDX) stock options?

The options have an exercise price of $34.09 per share. This means Arthur can acquire Celldex common stock at $34.09 per share once the options become exercisable according to the grant’s vesting terms.

When do Neil Garry Arthur’s Celldex (CLDX) options vest and expire?

The options become exercisable starting June 25, 2027, and expire on June 25, 2036. After the expiration date, any unexercised options from this 26,000-share grant will no longer be usable.

Were Neil Garry Arthur’s Celldex (CLDX) options granted under a specific equity plan?

Yes. The Form 4 states the options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan. This plan governs equity-based compensation awards such as stock options for eligible participants at the company.